Gastroenterology

  • Home
  • Gastroenterology
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Condition:   Ulcerative Colitis
Interventions:   Drug: UTTR1147A;   Drug: UTTR1147A Placebo;   Drug: Vedolizumab;   Drug: Vedolizumab Placebo
Sponsor:   Genentech, Inc.
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 15, 2018 / by / in
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett’s Esophagus/Esophageal Adenocarcinoma

Conditions:   Barrett’s Esophagus;   Esophageal Adenocarcinoma
Intervention:   Other: EMR and RFA effect on stem cell marker expression in BE/EAC
Sponsor:   University of Oklahoma
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 17, 2018 / by / in
Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares

Condition:   Colitis, Ulcerative
Intervention:   Other: Hyperbaric Oxygen Therapy
Sponsors:   Dartmouth-Hitchcock Medical Center;   Foundation for Clinical Research in IBD;   The Eli and Edythe Broad Foundation;   University of California, San Diego;   Mayo Clinic;   University of Pittsburgh;   Virginia Mason Memorial Hospital;   University of Texas Southwestern Medical Center
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

April 14, 2018 / by / in
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Conditions:   c-MET Gene Amplification;   MET Exon 14 Mutation;   Metastatic Non-Squamous Non-Small Cell Lung Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   RET/PTC Rearrangement;   ROS1 Gene Rearrangement;   Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Sponsor:   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

April 11, 2018 / by / in
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Condition:   Nonalcoholic Steatohepatitis
Interventions:   Drug: SEL;   Drug: GS-0976;   Drug: GS-9674;   Drug: SEL Placebo;   Drug: GS-0976 Placebo;   Drug: GS-9674 Placebo
Sponsor:   Gilead Sciences
Recruiting
ClinicalTrials.gov: Gastroenterology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

April 10, 2018 / by / in